"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – and potentially even its domicile – according to an unconfirmed media ...

Highwire names 5W, Ketchum alum Michael O’Brien as CEO Jess Ruderman May 15, 2025 ‘Hollywood can impact change’: Ryan Reynolds on raising awareness about Parkinson’s-related hallucinations Lecia ...

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate ...